David Bonnet, MD
Family Medicine · Richardson, TXNPI 1982612180
Payments from drug & device makers
Across 277 payments — averaging $17.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$444
- Boehringer Ingelheim$437
- Johnson & Johnson$365
- GSK$282
- Lilly USA, LLC$224
- plus $2K from 34 others
What the payments were for
- Food & beverage$4,721100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 75 | $1,165 |
| AbbVie(2 entities) | 25 | $444 |
| Boehringer Ingelheim | 20 | $437 |
| Johnson & Johnson | 23 | $365 |
| GSK | 18 | $282 |
| Lilly USA, LLC | 12 | $224 |
| Merck | 16 | $223 |
| Genentech USA, Inc. | 9 | $160 |
| Novo Nordisk | 9 | $141 |
| Pfizer | 6 | $123 |
| Biohaven Pharmaceuticals, Inc. | 5 | $95 |
| Validus Pharmaceuticals LLC | 4 | $90 |
| Sanofi Pasteur Inc. | 4 | $84 |
| Eisai Inc. | 4 | $71 |
| Amarin Pharma, Inc. | 3 | $68 |
| Idorsia Pharmaceuticals US Inc | 4 | $68 |
| Alfasigma USA, Inc. | 4 | $57 |
| Astellas Pharma US Inc | 3 | $53 |
| Arbor Pharmaceuticals, Inc. | 3 | $49 |
| Tersera Therapeutics LLC | 3 | $41 |
| Nestle Healthcare Nutrition Inc. | 2 | $41 |
| Antares Pharma, Inc. | 2 | $40 |
| Medtronic | 2 | $40 |
| Nevro Corp. | 2 | $37 |
| Amgen(2 entities) | 2 | $35 |
| Amneal Pharmaceuticals LLC | 2 | $33 |
| Clarus Therapeutics Inc. | 2 | $32 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
| Paratek Pharmaceuticals, Inc. | 1 | $20 |
| Bayer | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Novartis | 1 | $19 |
| Aytu Biopharma, Inc. | 1 | $19 |
| Dexcom, Inc. | 1 | $18 |
| Acerus Pharmaceuticals Corporation | 1 | $18 |
| Abbott | 1 | $18 |
| Ironwood Pharmaceuticals, Inc | 1 | $17 |
| Cala Health, Inc. | 1 | $15 |
| Scilex Pharmaceuticals Inc. | 1 | $11 |
| Nabriva Therapeutics, PLC | 1 | $11 |
How this compares
$4,726 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 138 | $151,690 |
| JardianceEmpagliflozin | 55 | $76,998 |
| JanuviaSitagliptin Phosphate | 55 | $71,408 |
| OzempicSemaglutide | 34 | $47,860 |
| XareltoRivaroxaban | 35 | $35,386 |
| JanumetSitagliptin Phos/Metformin Hcl | 36 | $27,386 |
| EliquisApixaban | 22 | $20,905 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 29 | $20,603 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $19,068 |
| PremarinEstrogens, Conjugated | 29 | $12,774 |
| SynthroidLevothyroxine Sodium | 124 | $9,611 |
| Arnuity ElliptaFluticasone Furoate | 19 | $8,442 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 39 | $8,418 |
| Meloxicam | 731 | $5,100 |
| Wixela InhubFluticasone Propion/Salmeterol | 15 | $4,523 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere | $1,165 | $172,293167 claims |
| MerckJanuvia, Janumet | $223 | $98,79491 claims |
| Boehringer IngelheimJardiance | $437 | $76,99855 claims |
| Novo NordiskOzempic | $141 | $47,86034 claims |
| Johnson & JohnsonXarelto | $365 | $35,38635 claims |
| PfizerEliquis, Premarin | $123 | $33,67951 claims |
| GSKBreo Ellipta, Arnuity Ellipta | $282 | $27,51042 claims |
| AbbVieSynthroid | $444 | $9,611124 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $33 | $1,446177 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Richardson
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.